1. Home
  2. ONCY vs PMN Comparison

ONCY vs PMN Comparison

Compare ONCY & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.79

Market Cap

98.7M

Sector

Health Care

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$10.36

Market Cap

115.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONCY
PMN
Founded
1998
2004
Country
Canada
Canada
Employees
29
N/A
Industry
Pharmaceuticals and Biotechnology
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.7M
115.5M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
ONCY
PMN
Price
$0.79
$10.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$7.33
$42.67
AVG Volume (30 Days)
1.1M
29.6K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,505.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.29
52 Week High
$1.51
$27.40

Technical Indicators

Market Signals
Indicator
ONCY
PMN
Relative Strength Index (RSI) 33.09 42.61
Support Level N/A $10.55
Resistance Level $1.18 $13.80
Average True Range (ATR) 0.05 0.58
MACD -0.01 0.18
Stochastic Oscillator 12.01 64.38

Price Performance

Historical Comparison
ONCY
PMN

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: